Diagnostic and interventional imaging techniques in breast cancer
Publication date: Available online 22 February 2019Source: Surgery (Oxford)Author(s): Simon Lowes, Alice Leaver, Alan RedmanAbstractImaging plays a critical role in the diagnosis and management of breast cancer. Two-view mammography and ultrasound form the mainstay of breast imaging and are essential components of the triple assessment. Digital mammography is rapidly replacing analogue mammography, and recent advances such as digital tomosynthesis add a third dimension to conventional 2D mammographic images. The versatility of ultrasound allows assessment of the breast and axilla as well as accurately targeted interventions, from the simple diagnostic core biopsy to preoperative tumour localization. It also guides large volume biopsies and excision of certain benign lesions, which in some cases can obviate surgical excision. Newer ultrasound techniques being applied to the breast and axilla include elastography and the use of intradermal microbubbles to guide the radiologist to the sentinel axillary node. Breast MRI is a powerful modality in assessing breast cancer. It can provide accurate information on size and multifocality of lesions, particularly those that are mammographically challenging such as lobular cancers, and it is also used to assess response to neoadjuvant chemotherapy and guide surgical management. CT scans, and in selected cases Positron Emission Tomography, play important roles in the assessment of metastatic disease.
Structure and function of β-arrestins, their emerging role in breast cancer, and potential opportunities for therapeutic manipulation. Adv Cancer Res. 2020;145:139-156 Authors: Shukla AK, Dwivedi-Agnihotri H Abstract β-Arrestins (βarrs) are multifunctional intracellular proteins with an ability to directly interact with a large number of cellular partners including the G protein-coupled receptors (GPCRs). βarrs contribute to multiple aspects of GPCR signaling, trafficking and downregulation. Considering the central involvement of GPCR signaling in the onset and progression of diver...
Discussion. Genetic testing for BRCA1/2 mutation was not associated in our sample with increased level of psychological distress as measured with HADS in a short-term evaluation. PMID: 32089686 [PubMed]
Publication date: May 2020Source: Biomedicine &Pharmacotherapy, Volume 125Author(s): Bin Hua, Yao Li, Xin Yang, Xiaojuan Niu, Yanyang Zhao, Xiaoquan Zhu
Authors: Alotaibi RM, Guure C Abstract One of the major causes of death among females in Saudi Arabia is breast cancer. Newly diagnosed cases of breast cancer among the female population in Saudi Arabia is 19.5%. With this high incidence, it is crucial that we explore the determinants associated with breast cancer among the Saudi Arabia populace-the focus of this current study. The total sample size for this study is 8312 (8172 females and about 140 representing 1.68% males) patients that were diagnosed with advanced breast cancer. These are facility-based cross-sectional data collected over a 9-year period (2004 t...
Researchers from the Loma Linda University in California found drinking a third of a cup of milk every day, the equivalent of a small latte, spiked the risk by a third. Two cups saw it jump to nearly 80 per cent.
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the February 25, 2020 issue
Publication date: Available online 25 February 2020Source: Life SciencesAuthor(s): Jing Chen, Na Li, Boxia Liu, Jun Ling, Wenjun Yang, Xiufeng Pang, Tao Li
Healthy women age 75 and older may not benefit from continued breast cancer...Read more on AuntMinnie.comRelated Reading: Is breast screening beneficial for sickly older women? ACP pushes breast cancer screening start from 40 to 50 DBT screening mammography benefits women over 65 Screening mammography still good for older women Age, not density, predicts interval breast cancer result
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
(Loma Linda University Adventist Health Sciences Center) Intake of dairy milk is associated with a greater risk of breast cancer in women -- up to 80% depending on the amount consumed -- according to a new study conducted by researchers at Loma Linda University Health.